EGFR and non-small cell lung carcinoma: Although recent years have shown the discovery of many genetic drivers in NSCLC, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase fusion, and human telomerase reverse transcriptase overexpression, these drivers are at present the only therapeutic target genes for NSCLC 6-8.